Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

To elicit optimal immune responses, messenger RNA vaccines require intracellular delivery
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …

Human autoantibodies (auto‐Abs) neutralizing type I IFNs were first discovered in a woman
with disseminated shingles and were described by Ion Gresser from 1981 to 1984. They …

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is silent or benign
in most infected individuals, but causes hypoxemic COVID-19 pneumonia in about 10% of …

Host immunity to infection with SARS-CoV-2 is highly variable, dictating diverse clinical
outcomes ranging from asymptomatic to severe disease and death. We previously reported …

Abstract Background Auto-antibodies (auto-Abs) neutralizing type I interferons (IFN) have
been found in about 15% of critical cases COVID-19 pneumonia and less than 1% of mild or …

Warmer climatic conditions have been associated with fewer COVID-19 cases. Herein we
infected K18-hACE2 mice housed at the standard animal house temperature of∼ 22° C, or …

As COVID-19 evolves from a pandemic to an endemic disease, the already staggering
number of people that have been or will be infected with SARS-CoV-2 is only destined to …

Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively
inhibit viral replication, prevent virus-mediated tissue damages and promote innate and …

Background. Clinical and experimental evidence point to a dysregulated immune response
caused by SARS-CoV-2 as the primary mechanism of lung disease in COVID-19. However …